The study, known as the BeSolveRD trial and published in Genome Medicine, enrolled 567 individuals with unexplained developmental disorders between June 2021 and July 2024. Participants were randomized using blocked, center-specific lists into two arms: 283 received the standard diagnostic pathway, while 284 received whole genome sequencing. The trial was designed to answer a question that has divided clinical genetics for years — whether the extra information contained in the roughly 90 percent of the genome beyond the exome, the protein-coding fraction, translates into real diagnostic gains in routine hospital settings rather than in centralized reference laboratories.

The headline result was clear. Genome sequencing achieved a diagnostic yield of 39.8 percent, identifying a certain molecular diagnosis in 113 of 284 probands, compared with 30 percent — 85 of 283 — for the standard of care, a difference that was statistically significant (p = 0.015). When the researchers accounted for inherited variants in genes associated with autosomal dominant conditions, the gap widened further, with genome sequencing outperforming standard care by 9.8 percentage points, equivalent to a relative increase in diagnostic yield of 32.7 percent. Most of the added value came from better detection of single nucleotide variants and small insertions or deletions, which contributed an additional 8.7 percent of diagnoses in the genome sequencing arm.

The technical story behind those numbers is instructive. Genome sequencing offers more uniform coverage across the genome than exome sequencing, which relies on capture probes that can miss regions with poor sequence homology to the reference genome. In this trial, the researchers found that the exome data actually covered the genomic loci of nearly all genome-sequencing-detected variants at more than 20-fold depth, suggesting the advantage was not simply a matter of coverage drops. Instead, the most striking difference emerged in the detection of out-of-frame indels: 26 frameshift variants were identified in the genome sequencing arm versus only 10 in the standard care arm, a difference of 5.6 percent that reached statistical significance. The authors hypothesize that variants with lower sequence similarity to the reference genome may be less effectively captured by exome probes, leading to their underrepresentation in sequencing data.

Genome sequencing also uncovered diagnoses that exome-based approaches structurally cannot reach. Three non-coding or otherwise elusive pathogenic variants were detected, including a de novo variant in the 5′ untranslated region of MEF2C, a gene whose regulatory disruption causes severe developmental disorder; a short tandem repeat expansion in the promoter of FMR1, the cause of Fragile-X syndrome, one of the most prevalent forms of inherited intellectual disability in males; and two pathogenic SHANK3 frameshift variants that had been filtered out in routine analysis because of inflated frequency estimates in population databases. A small 5′ untranslated region deletion potentially downregulating ANKRD11, associated with KBG syndrome, was also identified only through genome sequencing. These findings illustrate the growing recognition that the non-coding genome, repeat expansions, and structural variation harbor a meaningful share of disease-causing variants that exome-centric pipelines miss.

Perhaps the most surprising finding of the trial concerned inherited variants. Clinical laboratories analyzing trio data typically prioritize de novo variants, X-linked variants, and autosomal recessive inheritance. But when the researchers systematically examined inherited variants in genes associated with autosomal dominant conditions, they found 22 additional diagnoses across both arms — 3.9 percent of the entire cohort — representing 11 percent of all certain diagnoses. For 18 of these 22 families, there had been no prior suspicion of a dominantly inherited disorder, and half of the carrier parents were reported to be asymptomatic, consistent with the variable expression and reduced penetrance described for these genes. The contribution of inherited dominant variants (3.9 percent) exceeded that of X-linked variants (1.9 percent) and matched that of autosomal recessive variants (4.1 percent). The authors argue this strongly favors including autosomal dominant inherited variants in the standard work-up for developmental disorders, even when parents appear unaffected — a practice with real clinical consequences, as illustrated by two maternally inherited pathogenic PTEN variants that carry implications for lifelong cancer surveillance.

The trial also revealed a striking and persistent sex difference. Females obtained a diagnosis in 45.5 percent of cases, compared with only 28.5 percent of males — a 17 percentage-point gap that remained significant across indication categories and even among probands with moderate to profound intellectual disability. Part of this difference may reflect the higher prevalence of autism and autistic behavior among males, since autism was associated with lower diagnostic yields in this cohort. But the pattern aligns with previous large exome analyses from the United Kingdom and Ireland showing lower odds of diagnosis in males, and with the hypothesis that females with neurodevelopmental disorders carry a higher burden of rare, high-impact variants, consistent with a female protective model. After adjusting for sex distribution and the additional analyses performed in the genome sequencing arm, the overall yield difference between the two strategies narrowed to 7.3 percent, which no longer reached conventional statistical significance (p = 0.069) — a nuance the authors report transparently.

What sets this trial apart from earlier comparisons is its setting. Most previous studies of genome sequencing relied on centralized reference or research laboratories, raising questions about whether the technology could deliver comparable performance in the decentralized, hospital-based laboratories where most patients are actually seen. The Belgian consortium implemented clinical-grade genome sequencing across five sequencing sites and eight clinical interpretation centers, each using its own validated wet-lab and bioinformatic protocols. Before recruitment, all centers participated in an inter-laboratory ring trial using Genome-In-A-Bottle reference samples, achieving consistently high precision and recall for variant calling despite differences in library preparation kits, fragmentation methods, and reference genome versions. This demonstrated that nationwide, multi-site implementation of clinical genome sequencing is feasible — and that its diagnostic utility in hospital settings may actually exceed that reported in external reference laboratories.

The study was not without limitations. Recruitment fell short of the initial target of 800 participants, reducing statistical power, and the trial was retrospectively registered. Over two-thirds of the cohort had already undergone negative copy-number analysis before enrollment, meaning the CNV detection advantage of genome sequencing was likely underestimated; in a true first-tier setting, where pathogenic copy-number variants are found in roughly 12 percent of patients, the gap in favor of genome sequencing could be wider. Short-read sequencing also remains blind to certain challenges: low-complexity repetitive regions, some structural variants, inversions, complex rearrangements, mosaic variants, and epigenetic abnormalities all persist as blind spots, though long-read technologies promise to address some of these constraints as costs fall.

The implications for clinical practice are substantial. Beyond raw diagnostic yield, genome sequencing consolidates what is currently a fragmented, sequential testing cascade — microarray, exome, and follow-up assays — into a single test that simultaneously detects single nucleotide variants, indels, copy-number variants, structural variants, and repeat expansions. That streamlining reduces turnaround time, a critical factor for critically ill newborns, and preserves the option of reanalysis as knowledge grows: a post hoc targeted look at the recently discovered RNU4-2 gene, implicated in roughly 0.5 percent of neurodevelopmental disorders, immediately yielded one additional diagnosis among the trial’s unsolved genome sequencing samples. With artificial intelligence-driven variant prioritization tools already contributing to the yield gains observed here, and with non-coding variant interpretation maturing rapidly, the authors anticipate the advantage of genome sequencing will only grow — strengthening the case for making it the first-line molecular test for children with unexplained developmental disorders.

Subject of Research: Genome sequencing versus standard of care for diagnosing developmental disorders

Article Title: A nationwide prospective randomized trial for diagnosing developmental disorders demonstrates genome sequencing outperforms standard of care

Article References: A nationwide prospective randomized trial for diagnosing developmental disorders demonstrates genome sequencing outperforms standard of care. (n.d.). https://doi.org/10.1186/s13073-026-01771-2

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01771-2

Keywords: genome sequencing, exome sequencing, developmental disorders, intellectual disability, congenital anomalies, diagnostic yield, randomized controlled trial, clinical genetics, non-coding variants, autosomal dominant inheritance, BeSolveRD trial, Genome Medicine

Retinitis pigmentosa, also known as rod-cone dystrophy, is one of the most genetically heterogeneous disorders in human medicine. It begins with the progressive loss of rod photoreceptors, the cells responsible for vision in dim light, which produces night blindness and narrowing of the visual field. As the disease advances, cone photoreceptors, which mediate daylight and color vision, degenerate as well, often culminating in severe visual impairment or legal blindness in midlife. Approximately forty genes have so far been linked to the autosomal dominant form of the disease, in which a single inherited copy of a pathogenic variant is sufficient to cause symptoms. Yet even with modern genetic testing, a stubborn fraction of patients never receives a molecular diagnosis.

That diagnostic gap was precisely what motivated the new study. The researchers, led by Isabelle Audo and Christina Zeitz of Sorbonne Université, INSERM, CNRS and the Institut de la Vision in Paris, together with colleagues at the Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts and partner institutions, analyzed a French cohort of 395 families with autosomal dominant retinitis pigmentosa and 418 genetically unsolved cases. Every participant underwent comprehensive ophthalmic examination, including standard-of-care retinal imaging and functional assessments, ensuring that the genetic findings could be interpreted against detailed clinical pictures. The team combined genome sequencing, direct Sanger sequencing and a candidate gene approach to interrogate regions of the genome that standard analyses often skip.

The regions they targeted belong to a family of genes with an unusual biology. Small nuclear RNA genes do not encode proteins; instead, they produce short RNA molecules that form the structural and catalytic core of the spliceosome, the cellular machine that removes intervening sequences from messenger RNA precursors. The U4 and U6 small nuclear RNAs associate with U5 snRNA and a set of proteins to build the tri-small nuclear ribonucleoprotein complex, or tri-snRNP, a central component of the major spliceosome. Because splicing is essential in every cell, one might expect defects in these genes to be lethal or to cause widespread damage. Instead, recent years have revealed a striking pattern: inherited and de novo variants in snRNA genes appear in people with recessive neurodevelopmental disorders, and, as the new work confirms, in people with inherited retinal degeneration.

What makes the retinal findings particularly intriguing is where the disease-causing variants sit within these small RNA genes. The variants associated with retinitis pigmentosa cluster in regions that are distinct from those implicated in neurodevelopmental disorders, and they affect domains involved in the assembly of the tri-snRNP with three proteins that retinitis specialists know well: PRPF3, PRPF8 and PRPF31. All three of these proteins are themselves established causes of autosomal dominant retinitis pigmentosa. In other words, the retina appears to be exquisitely sensitive to a specific kind of disruption in the splicing machinery, one that interferes with the assembly of the tri-snRNP complex, while other tissues tolerate it. This convergence of RNA genes and spliceosome protein genes on the same disease phenotype provides a coherent mechanistic thread through what had seemed like scattered genetic findings.

The results of the cohort screen were unambiguous. The researchers identified heterozygous inherited variants in RNU4-2 and in RNU6 paralogs in eight unrelated families with non-syndromic autosomal dominant retinitis pigmentosa. In every family where additional members were available for testing, the variant co-segregated with the disease, passing from affected parents to affected children exactly as an autosomal dominant mutation should. None of the affected individuals showed the extra-neurological features that might suggest a syndromal diagnosis; their disease was confined to the retina, reinforcing the idea that these snRNA variants produce a pure retinal phenotype rather than a broader developmental syndrome.

Translated into population terms, the eight families mean that variants in RNU4-2 or RNU6 paralogs account for two percent of the genetically solved individuals with autosomal dominant retinitis pigmentosa in the cohort. Perhaps more striking is the comparison the authors draw within the spliceosome category: these snRNA variants represent six percent of all individuals carrying variants in genes coding for the multi-subunit spliceosome complex. A single family of non-coding RNA genes therefore contributes a non-trivial share of the spliceosome-related disease burden, a category that until now has been defined almost entirely by protein-coding genes such as PRPF31, PRPF8, PRPF3, PRPF4, PRPF6, SNRNP200 and RP9. The message for diagnostics is clear: excluding snRNA genes from analysis leaves a measurable fraction of patients without answers.

Why have these genes escaped detection for so long? The answer lies partly in the mechanics of genome analysis. Small nuclear RNA genes are short, repetitive and often present in multiple copies or paralogs scattered across the genome, which complicates the alignment of sequencing reads and the confident calling of variants. Many bioinformatics pipelines are tuned to detect single nucleotide changes in protein-coding exons and simply do not report variants in these loci, even when the underlying sequence data contain them. The French team’s use of genome sequencing combined with targeted Sanger validation illustrates the practical path forward: once a candidate snRNA variant is flagged, conventional sequencing can confirm it and family studies can establish segregation. The bottleneck is not the technology but the willingness to look in places the standard tools ignore.

The clinical implications extend beyond diagnosis. A confirmed molecular diagnosis is the gateway to genetic counseling, allowing affected individuals to understand the inheritance pattern and recurrence risk in their families, and to reproductive options such as preimplantation genetic testing. It is also increasingly the entry ticket to precision therapy, as gene-specific clinical trials for inherited retinal disease multiply. For the two percent of autosomal dominant retinitis pigmentosa patients who carry RNU4-2 or RNU6 paralog variants, inclusion of snRNA genes in diagnostic panels could mean the difference between an unsolved case and eligibility for emerging interventions. The finding also suggests that other unexplained retinal degenerations might owe their existence to additional non-coding RNA genes waiting to be interrogated.

Scientifically, the study strengthens an emerging view of the spliceosome as a hotspot for tissue-specific disease. The retina, with its extraordinarily high metabolic demands and its photoreceptors’ constant need to renew outer segment proteins, appears uniquely vulnerable to partial defects in RNA processing that other tissues can buffer. The clustering of retinal disease variants in tri-snRNP assembly domains, distinct from the regions implicated in neurodevelopmental disorders, hints at a genotype-phenotype map within molecules barely a hundred nucleotides long. As genome sequencing becomes the default first test for rare disease, the French cohort results argue that the small RNAs at the heart of the spliceosome deserve a permanent place on the diagnostic checklist, both for the patients they will finally explain and for the biology they continue to reveal.

Subject of Research: Small nuclear RNA gene variants causing autosomal dominant retinitis pigmentosa

Article Title: Variants in RNU4-2 or RNU6 paralogs account for 2% of individuals with non-syndromic autosomal dominant retinitis pigmentosa in a large French cohort

Article References: Audo, I., Navarro, J., Bianco, L., Antropoli, A., Condroyer, C., Antonio, A., Andrieu, C., Mohand-Saïd, S., Laurent-Coriat, C., Atia, R., Benadji, A., Smirnov, V., Sahel, J.-A., & Zeitz, C. (2026). Variants in RNU4-2 or RNU6 paralogs account for 2% of individuals with non-syndromic autosomal dominant retinitis pigmentosa in a large French cohort. Genome Medicine. https://doi.org/10.1186/s13073-026-01743-6

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01743-6

Keywords: retinitis pigmentosa, RNU4-2, RNU6, small nuclear RNA, spliceosome, tri-snRNP, inherited retinal disease, genome sequencing, autosomal dominant inheritance, RNA splicing, genetic diagnosis, French cohort